Clinical Trial Detail

NCT ID NCT03422536
Title Ficlatuzumab With or Without Cetuximab in Treating Patients With Cetuximab-Resistant, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Arizona
Indications

auditory system cancer

lip cancer

paranasal sinus cancer

nasopharynx carcinoma

head and neck squamous cell carcinoma

Therapies

Ficlatuzumab

Cetuximab + Ficlatuzumab

Age Groups: adult senior

No variant requirements are available.